Haemonetics (HAZ) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HAZ Analyst Ratings

Moderate Buy

6 Buy

3 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Haemonetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HAZ Stock 12 Month Forecast

Average Price Target

€81.67

▲(19.23% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Haemonetics in the last 3 months. The average price target is €81.67 with a high forecast of €91.11 and a low forecast of €72.89. The average price target represents a 19.23% change from the last price of €68.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"€39","92":"€92","52.25":"€52.3","65.5":"€65.5","78.75":"€78.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":91.10858295,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€91.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81.67233685875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€81.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.88686636,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€72.89</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,52.25,65.5,78.75,92],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73,74.39296791923077,75.78593583846154,77.17890375769231,78.57187167692308,79.96483959615385,81.35780751538462,82.75077543461538,84.14374335384615,85.53671127307692,86.92967919230769,88.32264711153846,89.71561503076923,{"y":91.10858295,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73,73.66710283528846,74.33420567057692,75.00130850586538,75.66841134115384,76.3355141764423,77.00261701173076,77.66971984701924,78.3368226823077,79.00392551759616,79.67102835288462,80.33813118817308,81.00523402346154,{"y":81.67233685875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73,72.99129741230769,72.98259482461539,72.97389223692308,72.96518964923077,72.95648706153847,72.94778447384616,72.93908188615384,72.93037929846153,72.92167671076923,72.91297412307692,72.90427153538461,72.89556894769231,{"y":72.88686636,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€91.11

Average Price Target€81.67

Lowest Price Target€72.89

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joanne Wuensch

Citi

€79.83

Hold

16.54%

Upside

Reiterated

08/13/26

Haemonetics (HAE) Receives a Hold from Citi

Travis Steed

Bank of America Securities

€86.77

Buy

26.67%

Upside

Assigned

08/12/26

Haemonetics (HAE) Gets a Buy from Bank of America Securities

Anthony Petrone

Mizuho Securities

€78.09→€82.43

Buy

20.34%

Upside

Reiterated

08/11/26

Mizuho Securities Reaffirms Their Buy Rating on Haemonetics (HAE)

Allen Gong

J.P. Morgan

€74.62

Hold

8.94%

Upside

Reiterated

08/10/26

J.P. Morgan Sticks to Its Hold Rating for Haemonetics (HAE)

David Rescott

Robert W. Baird

€76.36→€83.3

Buy

21.60%

Upside

Reiterated

08/07/26

Haemonetics price target raised to $96 from $88 at BairdHaemonetics price target raised to $96 from $88 at Baird

Michael Petusky

Barrington

€77.23→€82.43

Buy

20.34%

Upside

Reiterated

08/07/26

Haemonetics price target raised to $95 from $89 at BarringtonHaemonetics price target raised to $95 from $89 at Barrington

Andrew Cooper

Raymond James

€78.09→€91.11

Buy

33.01%

Upside

Reiterated

08/07/26

Haemonetics price target raised to $105 from $90 at Raymond JamesHaemonetics price target raised to $105 from $90 at Raymond James

Michael Matson

Needham

―

Hold

―

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Haemonetics (NYSE: HAE) and Nuvation Bio (NYSE: NUVB)

Marie Thibault

BTIG

€72.89

Buy

6.40%

Upside

Reiterated

06/26/26

Analysts Conflicted on These Healthcare Names: Haemonetics (NYSE: HAE) and Health Catalyst (NASDAQ: HCAT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joanne Wuensch

Citi

€79.83

Hold

16.54%

Upside

Reiterated

08/13/26

Haemonetics (HAE) Receives a Hold from Citi

Travis Steed

Bank of America Securities

€86.77

Buy

26.67%

Upside

Assigned

08/12/26

Haemonetics (HAE) Gets a Buy from Bank of America Securities

Anthony Petrone

Mizuho Securities

€78.09→€82.43

Buy

20.34%

Upside

Reiterated

08/11/26

Mizuho Securities Reaffirms Their Buy Rating on Haemonetics (HAE)

Allen Gong

J.P. Morgan

€74.62

Hold

8.94%

Upside

Reiterated

08/10/26

J.P. Morgan Sticks to Its Hold Rating for Haemonetics (HAE)

David Rescott

Robert W. Baird

€76.36→€83.3

Buy

21.60%

Upside

Reiterated

08/07/26

Haemonetics price target raised to $96 from $88 at BairdHaemonetics price target raised to $96 from $88 at Baird

Michael Petusky

Barrington

€77.23→€82.43

Buy

20.34%

Upside

Reiterated

08/07/26

Haemonetics price target raised to $95 from $89 at BarringtonHaemonetics price target raised to $95 from $89 at Barrington

Andrew Cooper

Raymond James

€78.09→€91.11

Buy

33.01%

Upside

Reiterated

08/07/26

Haemonetics price target raised to $105 from $90 at Raymond JamesHaemonetics price target raised to $105 from $90 at Raymond James

Michael Matson

Needham

―

Hold

―

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Haemonetics (NYSE: HAE) and Nuvation Bio (NYSE: NUVB)

Marie Thibault

BTIG

€72.89

Buy

6.40%

Upside

Reiterated

06/26/26

Analysts Conflicted on These Healthcare Names: Haemonetics (NYSE: HAE) and Health Catalyst (NASDAQ: HCAT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Haemonetics

3 Months

Andrew CooperRaymond James

Success Rate

8/12 ratings generated profit

Average Return

+6.18%

Copying Andrew Cooper's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +6.18% per trade.

1 Year

Andrew CooperRaymond James

Success Rate

9/12 ratings generated profit

Average Return

+19.41%

Copying Andrew Cooper's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +19.41% per trade.

2 Years

Andrew CooperRaymond James

Success Rate

12/12 ratings generated profit

Average Return

+33.58%

Copying Andrew Cooper's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +33.58% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HAZ Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HAZ has received 12 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. HAZ average Analyst price target in the past 3 months is 81.67.

Each month's total comprises the sum of three months' worth of ratings.

HAZ Financial Forecast

HAZ Earnings Forecast

Next quarter’s earnings estimate for HAZ is €1.12 with a range of €1.05 to €1.19. The previous quarter’s EPS was €0.99. HAZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HAZ has Performed in-line its overall industry.

HAZ Sales Forecast

Next quarter’s sales forecast for HAZ is €299.04M with a range of €292.94M to €307.45M. The previous quarter’s sales results were €294.14M. HAZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HAZ has Performed in-line its overall industry.

HAZ Stock Forecast FAQ

What is DE:HAZ’s average 12-month price target, according to analysts?

Based on analyst ratings, Haemonetics Corp.’s 12-month average price target is 81.67.

What is DE:HAZ’s upside potential, based on the analysts’ average price target?

Haemonetics Corp. has 19.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Haemonetics Corp. a Buy, Sell or Hold?

Haemonetics Corp. has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.

What is Haemonetics Corp.’s share price target?

The average share price target for Haemonetics Corp. is 81.67. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €91.11 ,and the lowest forecast is €72.89. The average share price target represents 19.23% Increase from the current price of €68.5.

What do analysts say about Haemonetics Corp.?

Haemonetics Corp.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Haemonetics Corp.?

To buy shares of DE:HAZ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Haemonetics (HAZ) Stock Forecast & Price Target

HAZ Analyst Ratings

HAZ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Haemonetics

HAZ Analyst Recommendation Trends

HAZ Financial Forecast

HAZ Earnings Forecast

HAZ Sales Forecast

HAZ Stock Forecast FAQ

Detailed List of Analyst Forecasts